Patents by Inventor David Diemert

David Diemert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ENGINEERED HUMAN HOOKWORMS AS A NOVEL BIODELIVERY SYSTEM FOR VACCINES AND BIOLOGICALS
    Publication number: 20190069528
    Abstract: The present disclosure generally relates to genetic methods of manipulating helminths, e.g., hookworms, to act as a biological delivery vehicle for therapeutic polypeptides in mammals. Furthermore, the disclosure is drawn to compositions comprising genetically modified hookworms and methods of use, including the administration of the helminths to one or more mammals to provide a continuous supply of a synthetic or modified polypeptide (e.g., HIV neutralizing antibodies) which may mitigate infection and/or infection intensity, otherwise resulting in an increase in a desirable phenotypic trait.
    Type: Application
    Filed: March 21, 2017
    Publication date: March 7, 2019
    Inventors: John M. HAWDON, Douglas NIXON, Suhao HAN, Claudia BROCKMEYER, Jeffrey BETHONY, Ramesh RATNAPPAN, David DIEMERT
  • Multivalent antihelminthic vaccine
    Patent number: 8444994
    Abstract: A multivalent anthelmintic vaccine targets both hookworm and schistosomiasis. The vaccine includes, at a minimum, a recombinant third-stage larval hookworm antigen, a recombinant adult stage hookworm antigen, and a recombinant schistosome antigen. Preferably, the hookworm antigens are Necator americanus antigens, although antigens from other hookworm species (e.g. Ancylostoma duodenale) may also be employed. The schistosome antigen is preferably a Schistosoma mansoni or a Schistosoma haematobium antigen although antigens from other schistosome species (e.g. Schistosoma japonicum) may also be employed. In some cases full or partial sequences of schistosome antigens may be fused with full or partial sequences of hookworm {Necator americanus) to produce recombinant chimeric antigens.
    Type: Grant
    Filed: June 30, 2009
    Date of Patent: May 21, 2013
    Assignees: The Albert B. Sabin Vaccine Institute, The George Washington University, The Council of the Queensland Institute of Medical Research
    Inventors: Peter Hotez, Alexander Loukas, Mark Pearson, Jeffrey Bethony, Bin Zhan, Gaddam Goud, Maria Elena Bottazzi, David Diemert, Ami Shah Brown, Peter Giacomautonio
  • MULTIVALENT ANTIHELMINTHIC VACCINE
    Publication number: 20110200640
    Abstract: A multivalent anthelmintic vaccine targets both hookworm and schistosomiasis. The vaccine includes, at a minimum, a recombinant third-stage larval hookworm antigen, a recombinant adult stage hookworm antigen, and a recombinant schistosome antigen. Preferably, the hookworm antigens are Necator americanus antigens, although antigens from other hookworm species (e.g. Ancylostoma duodenale) may also be employed. The schistosome antigen is preferably a Schistosoma mansoni or a Schistosoma haematobium antigen although antigens from other schistosome species (e.g. Schistosoma japonicum) may also be employed. In some cases full or partial sequences of schistosome antigens may be fused with full or partial sequences of hookworm {Necator americanus) to produce recombinant chimeric antigens.
    Type: Application
    Filed: June 30, 2009
    Publication date: August 18, 2011
    Inventors: Peter Hotez, Alexander Loukas, Mark Pearson, Jeffrey Bethony, Bin Zhan, Gaddam Goud, Maria Elena Bottazzi, David Diemert, Ami Shah Brown, Peter Giacomantonio